Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III study of margetuximab plus retifanlimab or tebotelimab with chemotherapy in untreated HER2-positive advanced gastric or gastroesophageal junction cancer
CTR20200660Phase 3Suspended
- Sponsor
- Zai Lab
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of margetuximab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Zai Lab. Started Dec 2020; status: suspended.
02
Drugs
margetuximab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20200660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200660.